Irlanda - anglès - HPRA (Health Products Regulatory Authority)

imbat limited - mirtazapine - orodispersible tablet - 15 milligram(s) - other antidepressants; mirtazapine

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - mirtazapine, quantity: 45 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; lactose; hyprolose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of major depression including relapse prevention.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

lymphedonna pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - mirtazapine -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - mirtazapine -

Canadà - anglès - Health Canada

abbvie corporation - ombitasvir; paritaprevir; ritonavir - tablet - 12.5mg; 75mg; 50mg - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg - hcv protease inhibitors

Estats Units - anglès - NLM (National Library of Medicine)

harmony biosciences, llc - pitolisant hydrochloride (unii: yv33ch63hi) (pitolisant - unii:4bc83l4piy) - wakix is indicated for the treatment of excessive daytime sleepiness (eds) or cataplexy in adult patients with narcolepsy. wakix is contraindicated in patients with: - known hypersensitivity to pitolisant or any component of the formulation. anaphylaxis has been reported in patients treated with wakix [see adverse reactions (6.2)] . - severe hepatic impairment. wakix is extensively metabolized by the liver and there is a significant increase in wakix exposure in patients with moderate hepatic impairment [see use in specific populations (8.6)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to wakix during pregnancy. patients should be encouraged to enroll in the wakix pregnancy registry if they become pregnant. to enroll or obtain information from the registry, patients can call 1-800-833-7460. risk summary available case reports from clinical trials and postmarketing reports with wakix use in pregnant women have not determined a d

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexamfetamine sulfate 5mg - tablet - 5 mg - active: dexamfetamine sulfate 5mg excipient: lactose magnesium stearate povidone wheat starch - the treatment of well-established and proven narcolepsy.